A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: A randomized, single-blind study

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Prosser, James M ^a   Yard, Samantha ^b   Steele, Annie ^a   Cohen, Lisa J ^a   Galynker, Igor I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; RISPERIDONE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PANIC; PANIC DISORDER SEVERITY SCALE; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SEDATION; SHEEHAN PANIC ANXIETY SCALE PATIENT; SIDE EFFECT; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HOSPITALIZATION; PSYCHOLOGICAL ASPECT; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PANIC DISORDER; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 67649218436     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-25     Document Type: Article

References (72)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Text Revision Washington, DC: American Psychiatric Association Fourth 2000
2. Zvolensky MJ Bernstein A Marshall EC Feldner MT Panic attacks, panic disorder, and agoraphobia: Associations with substance use, abuse, and dependence Curr Psychiatry Rep 2006, 8(4):279-85. 10.1007/ s11920-006-0063-6 16879791
3. Coplan JD Poppa LA Pine D Clinical improvement with Fluoxetine therapy and noradrenergic function in patients with panic disorders Arch Gen Psychiatry 1997, 54:643-648. 9236548
4. Neumeister A Bain E Nugent AC Reduced serotonin A1 receptor binding in panic disorder J Neurosci 2004. 24:589-591. 10.1523/ JNEUROSCI.4921-03.2004 14736842
5. Maron E Shlik J Serotonin function in panic disorder: Important, but why? Neuropsychopharmacology 2006, 31(1):1-11. 16132063
6. Westenberg HG Leibowitz MR Overview of Panic and Social Anxiety Disorders J Clin Psychiatry 2004, 65(suppl 14):22-26. 15554785
7. Asnis GM Hameedi FA Goddard AW Fluvoxamine in the treatment of panic disorder: A multi-center, double-blind, placebo-controlled study in outpatients Psychiatry Res 2001, 103:1-14. 10.1016/S0165-1781(01)00265-7 11472786
8. Pollack M The pharmacotherapy of panic disorder J Clin Psychiatry 2005, 66(suppl 4):23-27. 15842184
9. Pollack MH Lepola U Koponen H Simon NM Worthington JJ Emilien G Tzanis E Salinas E Whitaker T Gao B A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder Depress Anxiety 2007, 24(1):1-14. 10.1002/da.20218 16894619
10. Sheehan DV Burnham DB Iyengar MK Perera P Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder J Clin Psychiatry 2005, 66(1):34-40. 15669886
11. Dannon PN Iancu I Cohen A Lowengrub K Grunhaus L Kotler M Three year naturalistic outcome study of panic disorder patients treated with paroxetine BMC Psychiatry 2004, 11(4):16. 10.1186/1471-244X-4-16
12. Bandelow B Ruther E Treatment-resistant panic disorder CNS Spectr 2004, 9(10):725-39. 15448584
13. Perna G Bertani A Caldirola D Smeraldi E Bellodi L A comparison of citalopram and paroxetine in the treatment of panic disorder: A randomized, single-blind study Pharmacopsychiatry 2001, 34(3):85-90. 10.1055/s-2001-14283 11434404
14. Toni C Perugi G Frare F Mata B Vitale B Mengali F Recchia M Serra G Akiskal HS A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants Pharmacopsychiatry 2000, 33(4):121-31. 10.1055/s-2000-11221 10958260
15. Ballenger JC Wheadon DE Steiner M Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorders Am J Psychiatry 1998, 155:36-42. 9433336
16. Lader M Management of panic disorder Expert Rev Neurother 2005, 5(2):259-66. 10.1586/14737175.5.2.259 15853495
17. Bakker A van Balkom AJ Stein DJ Evidence-based pharmacotherapy of panic disorder Int J Neuropsychopharmacol 2005, 8(3):473-82. 10.1017/ S1461145705005201 15804373
18. Pollack MH Allgulander C Bandelow B Cassano GB Greist JH Hollander E Nutt DJ Okasha A Swinson RP WCA recommendations for the long-term treatment of panic disorder CNS Spectr 2003, 8(8 Suppl 1):17-30. 14767395
19. Sepede G De Berardis D Gambi F Campanella D La Rovere R D'Amico M Cicconetti A Penna L Peca S Carano A Mancini E Salerno RM Ferro FM Olanzapine augmentation in treatment-resistant panic disorder: A 12-week, fixed-dose, open-label trial J Clin Psychopharmacol 2006, 26(1):45-9. 10.1097/01.jcp.0000195108.01898.17 16415705
20. Goodwin RD Faravelli C Rosi S Cosci F Truglia E de Graaf R Wittchen HU The epidemiology of panic disorder and agoraphobia in Europe Eur Neurpsychopharmacol 2005, 15:435-443. 10.1016/j.euroneuro.2005.04.006
21. Rickels K Schweizer E Panic disorder: Long-term pharmacotherapy and discontinuation J Clin Psychopharmacol 1998, 18(6 Suppl 2):12S-18S. 10.1097/00004714-199812001-00004 9872708
22. Conley RR Mahmoud R A randomized, double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder Am J Psychiatry 2001, 158:765-774. 10.1176/appi.ajp.158.5.765 11329400
23. Peuskens J Van Baelen B De Smedt C Lemmens P Effects of risperidone on affective symtpoms in patients with schizophrenia Int Clin Psychophamacol 2000, 15:343-49. 10.1097/00004850-200015060-00005
24. Kaplan M Atypical antipsychotics for treatment of mixed depression and anxiety J Clin Psychiatry 2000, 61:388-9. 10847317
25. Galynker I Khan A Grebchenko Y Ten A Malaya L Yanowitch P Cohen LJ Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression J Clin Psychiatry 2005, 66:544. 15816805
26. Morinigo A Blanco M Labrador J Martine J Noval D Risperidone for resistant anxiety in elderly persons Am J Geriatr Psychiatry 2005, 13:81-82. 15653944
27. Brawman-Mintzer O Knapp RG Nietert PJ Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study J Clin Psychiatry 2005, 66:1321-1325. 16259547
28. McDougle CJ Epperson CN Pelton GH Wasylink S Price LH A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder Arch Gen Psychiatry 2000, 57:794-801. 10.1001/archpsyc.57.8.794 10920469
29. Hollander E Baldini Rossi N Sood E Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study Int J Neuropsychopharmacol 2003, 63:397-401. 10.1017/S1461145703003730
30. Li X May RS Tolbert LC Jackson WT Flournoy JM Baxter LR Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: A crossover study J Clin Psychiatry 2005, 66:736-43. 15960567
31. Erzegovesi S Guglielmo E Silipriandi F Bellodi L Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study Eur Neuropsychopharmacol 2005, 15:69-74. 10.1016/j.euroneuro.2004.04.004 15572275
32. Bartzokis G Lu PH Turner J Mintz J Saunders CS Adjunctive risperidone in the treatment of chronic combat-related post-traumatic stress disorder Biol Psychiatry 2004, 57:474-479. 10.1016/j.biopsych.2004.11.039
33. Hamner MB Faldowski RA Ulmer HG Frueh BC Huber MG Arana GW Adjunctive risperidone treatment in post-traumatic stress disorder: A preliminary controlled trial of effects on comorbid psychotic symptoms Int Clin Psychopharmacol 2002, 18:1-8. 10.1097/00004850-200301000-00001
34. Monnelly EP Ciraulo DA Knapp C Keane T Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder J Clin Psychopharmacol 2003, 23:193-6. 10.1097/ 00004714-200304000-00012 12640221
35. Kozaric-Kovacic D Pivac N Muck-Seler D Rothbaum BO Risperidone in psychotic combat-related posttraumatic stress disorder: An open trial J Clin Psychiatry 2005, 66:922-927. 16013909
36. Lecrubier Y The impact of comorbidity on the treatment of panic disorder J Clin Psychiatry 1998, 59(Suppl 8):11-14. 9707157
37. Dunner DL The issue of comorbidity in the treatment of panic Int Clin Psychopharmacol 1998, 13(Suppl 4):S19-24. 9690961
38. Kessler RC Stang PE Wittchen HU Ustun TB Roy-Burne PP Walters EE Lifetime panic-depression comorbidity in the National Comorbidity Survey Arch Gen Psychiatry 1998, 55(9):801-8. 10.1001/archpsyc.55.9.801 9736006
39. Melartin TK Rytsala HJ Leskela US Lestela-Mielonen PS Sokero TP Isometsa ET Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study J Clin Psychiatry 2002, 63(2):126-34. 11874213
40. Weissman MM Wickramaratne P Adams PB Lish JD Horwath E Charney D Woods SW Leeman E Frosch E The relationship between panic disorder and major depression. A new family study Arch Gen Psychiatry 1994, 51(11):926-7. 7944881
41. Kaufman J Charney D Comorbidity of mood and anxiety disorders Depress Anxiety 2000, 12(Suppl 1):69-76. 10.1002/1520-6394(2000)12:1+ <69::AID-DA9>3.0.CO;2-K 11098417
42. Reich J Warshaw M Peterson LG White K Keller M Lavori P Yonkers KA Comorbidity of panic and major depressive disorder J Psychiatr Res 1993, 27(Suppl 1):23-33. 10.1016/0022-3956(93)90015-T 8145180
43. Gorman J Shear K Cowley D Cross CD March J Roth W Shehi M Wang PS Practice guidelines for the treatment of patients with panic disorder http://www.psychiatryonline.com/pracGuide/pracGuideTopic_9.aspx
44. Hamilton M A rating scale for depression J Neurol Neurosurg Psychiatry 1960, 23:56-62. 495331 14399272 10.1136/jnnp.23.1.56
45. Hamilton M Development of a rating scale for primary depressive illness Br J Soc Clin Psychol 1967, 6(4):278-96. 6080235
46. Moritz S Meier B Hand I Schick M Jahn H Dimensional structure of the Hamilton Depression Rating Scale in patients with obsessive-compulsive disorder Psychiatry Res 2004, 125:171-80. 10.1016/j.psychres.2003.11.003 15006440
47. Hamilton M The assessment of anxiety states by rating Br J Med Psychol 1959, 32:50-55. 13638508
48. Shear MK Rucci P Williams J Frank E Grochocinski V Bilt Vander J Houck P Wang T Reliability and validity of the Panic Disorder Severity Scale: replication and extension J Psychiatr Res 2001, 35(5):293-6. 10.1016/ S0022-3956(01)00028-0 11591432
49. Raj A Sheehan DV Medical evaluation of panic attacks J Clin Psychiatry 1987, 48(8):309-13. 3301823
50. Guy W Clinical Global Impressions ECDEU Assessment Manual Psychopharmacology, revised National Institute of Mental Health, Rockville MD 1976
51. Gibbons RD Hediker D Elkin I Waternaux C Kraemer HC Greenhouse JB Shea T Imber S Stotsky SM Watkins JT Some conceptual and statistical issues in analysis of longitudinal psychiatric data Arch Gen Psychiatry 1993, 50:739-750. 8357299
52. Laird NM Missing data in longitudinal studies Stat Med 1988, 7:305-315. 10.1002/sim.4780070131 3353609
53. Gehan EA A generalized Wilcoxon test for comparing arbitrarily singly-censored samples Biometrika 1965, 52(1-2):203-223. 14341275
54. Gao K Muzina D Gajwani P Calabrese JR Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders J Clin Psychiatry 2006, 67:1327-1340. 17017818
55. Simon NM Hoge EA Fischmann D Worthington JJ Christian JM Kinrys G Pollack MH An open-label trial of risperidone augmentation for refractory anxiety disorders J Clin Psychiatry 2006, 67:381-387. 16649823
56. Padala PR Madison J Monnahan M Marcil W Price P Ramaswamy S Din AU Wilson DR Petty F Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women Int Clin Psychopharmacol 2006, 21(5):275-80. 10.1097/00004850-200609000-00005 16877898
57. Megens AA Survey on the pharmacodynamics of the new antipsychotic risperidone Psychopharmacology Berl 1994, 114(1):9-23. 10.1007/ BF02245439 7531353
58. Nyberg S Farde L Eriksson L Halldin C Eriksson B 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone Psychopharmacology Berl 1993, 110(3):265-72. 10.1007/ BF02251280 7530376
59. Leysen JE Janssen PM Megens AA Schotte A Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity J Clin Psychiatry 1994, 55(Suppl):5-12. 7520908
60. Peeze MA Feldon J Mesolimbic dopaminergic pathways in fear conditioning Prog Neurobiol 2004, 74:301-320. 10.1016/j.pneurobio.2004.09.004 15582224
61. Yoshioka M Matsumoto M Togshi H Saito H Effect of conditioned fear stress on dopamine release in the rat prefrontal cortex Neurosci Lett 1996, 209:201-203. 10.1016/0304-3940(96)12631-8 8736645
62. Ladurelle N Roques BP Dauge V The transfer of rats from a familial to a novel environment prolongs the increase of extracellular dopamine efflux induced by CCK8 in the posterior nucleus accumbens J Neurosci 1995, 15:3118-3127. 7722650
63. Wedzony K Mackowiak M Fihal K Golembiowska K Evidence that conditioned stress enhances outflow of dopamine in the rat prefrontal cortex: A search for the influence of diazepam and 5-HT1A agonists Synapse 1996, 24:240-247. 10.1002/ (SICI)1098-2396(199611)24:3<240::AID-SYN6>3.0.CO;2-E 8923664
64. Inoue T Tsuchiya K Koyoma T Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear Pharmacol Biochem Behav 1996, 55:195-201. 10.1016/S0091-3057(96)00064-0 8951954
65. Ishida-Tokuda K Ohno Y Sakamoto H Ishibashi T Wakabayashi A Tojima R Morita T Nakamura M Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats Jpn J Pharmacol 1996, 72:119-126. 10.1254/jjp.72.119 8912913
66. Cavazutti E Bertoloni A Vergoni AV Arletti R Poggioli R Forgione A Benelli A 1-Sulpiride, at a low, non-neuroleptic dose, prevents conditioned fear stress-induced freezing behavior in rats Psychopharmacology (Berl) 1999, 143:20-23. 10.1007/s002130050914 10227075
67. Blier P Szabo ST Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety J Clin Psychiatry 2005, 66(suppl 8):30-40. 16336034
68. Szabo ST Blier P Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: A microiontophoretic study in the rat locus coeruleus Synapse 2001, 42:203-212. 10.1002/syn.10009 11746719
69. Stockmeier CA DiCarlo JJ Zhang Y Thompson P Meltzer HY Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther 1993, 266(3):1374-1384.
70. Dobscha SK Delucchi K Young ML Adherence with referrals for outpatient follow-up from a VA psychiatric emergency room Community Ment Health J 1999, 35(5):451-8. 10.1023/A:1018786512676 10547120
71. Killaspy H Banerjee S King M Lloyd M Prospective controlled study of psychiatric out-patient non-attendance. Characteristics and outcome Br J Psychiatry 2000, 176:160-5. 10.1192/bjp.176.2.160 10755054
72. Zvolensky M Bernstein A Cigarette smoking and panic psychopathology Curr Dir Psychological Sci 2005, 14:301-305. 10.1111/j.0963-7214.2005.00386.x